SCHEMBL5160571

SCHEMBL5160571

O=C(CC(=O)N1CCCCC1)c1cnc2ccccc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.58
KDM4E B2RXH2 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
HSD17B10 Q99714 2/20 0.58
RAB9A P51151 2/20 0.58
TP53 P04637 1/20 0.58
DPP4 P27487 2/20 0.53
MGAM O43451 1/20 0.51
CFTR P13569 1/20 0.48
PREP P48147 1/20 0.47
HPGD P15428 4/20 0.47
TSHR P16473 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CHRNB2 P17787 1/20 0.47
CHRNA7 P36544 1/20 0.47
CHRNA4 P43681 1/20 0.47
KDM2B Q8NHM5 1/20 0.47
ALDH1A1 P00352 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7100816 0.99 NPC1 (0.56) NPC1KDM4ESMN1; SMN2HSD17B10RAB9A
SCHEMBL5363975 0.78 MGAM (0.68) NPC1KDM4ESMN1; SMN2RAB9AMGAM
SCHEMBL9700485 0.76 MGAM (0.61) NPC1KDM4ESMN1; SMN2HSD17B10RAB9A
SCHEMBL7100632 0.76 MGAM (0.61) NPC1KDM4ESMN1; SMN2HSD17B10RAB9A
SCHEMBL5161032 0.76 DPP4 (0.51) NPC1KDM4ESMN1; SMN2HSD17B10RAB9A
SCHEMBL530208 0.76 TRPV1 (0.53) NPC1SMN1; SMN2RAB9AMGAMCFTR
SCHEMBL6692694 0.76 HPGD (0.59) NPC1KDM4ESMN1; SMN2RAB9AHPGD
Hydrochloric Acid SCHEMBL530298 0.75 TRPV1 (0.52) NPC1SMN1; SMN2RAB9AMGAMCFTR
SCHEMBL5161366 0.75 MAPT (0.52) NPC1KDM4ESMN1; SMN2RAB9AMGAM
SCHEMBL5160581 0.75 DPP4 (0.52) NPC1KDM4ESMN1; SMN2HSD17B10RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO NPC1 2400/4885KDM4E 862/4885SMN1; SMN2 4683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.